<DOC>
	<DOCNO>NCT02705508</DOCNO>
	<brief_summary>Extranodal natural killer/T-cell lymphoma ( ENKTL ) aggressive form non-Hodgkin 's lymphoma show extremely poor survival . This prospective pilot study evaluate efficacy safety pegylated aspargase ( PEG-ASP ) combine etoposide gemcitabine ( PEG ) treatment population .</brief_summary>
	<brief_title>PEG-ASP , Etoposide Gemcitabine Natural Killer/T Lymphoma</brief_title>
	<detailed_description>Treatment PEG dosages follow : day 1 8,30min intravenous infusion 1000mg/m2 gemcitabine ; day1,4h intravenous infusion 100mg/m2 etoposide , day1-3 , deep intramuscular injection 2500unit/m2 PEG-ASP three different sites.The regimen repeat every 3 weeks.Stage IE/IIE patient underwent four cycle induction chemotherapy , follow involved-field radiotherapy get complete remission , partial regression stable disease.Three-dimensional conformal radiotherapy do linear accelerator 2.0 gray ( Gy ) per daily fraction 5-6 week . The involved-field radiation ( IFRT ) dose 50-56 Gy.Stage IIIE/IVE patient give maximum six cycles.Refractory/relapsed patient underwent least two cycle treatment unless disease progression unacceptable side effect , withdrawal patient consent . Autologous haematopoietic stem cell transplantation ( AHSCT ) recommend achieve CR advance stage refractory/relapsed patient</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<criteria>1. pathologically confirm , previously untreated refractory/relapsed ENKTL define World Health Organization classification ; 2. age≥18 year ; 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; 4. least one measurable lesion ; 5. adequate haematologic function ( haemoglobin &gt; 9.0 g/l , absolute neutrophil count &gt; 1500/ml , platelet &gt; 75,000/l ) , 6. adequate hepatic function ( total serum bilirubin ≤ 1.5 time upper limit normal , alanine aminotransferase aspartate aminotransferase ≤ 2.5 time upper limit normal ) , 7. adequate renal function ( serum creatinine ≤ 1.5 mg/dl , creatinine clearance ≥ 50 ml/min ) ; 8. normal coagulation function electrocardiogram result . 9 . Prior chemotherapy radiotherapy complete &gt; 4 week 10.earlier , willingness provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>extranodal natural killer/T-cell lymphoma</keyword>
	<keyword>nasal type</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>radiotherapy</keyword>
</DOC>